Marisa Dolled-Filhart

MARISA DOLLED-FILHART, PhD is the scientific vice president of translational development for the BMS tumor microenvironment TRC, focusing on translational biomarker strategies and execution for early oncology trials. Dolled-Filhart is an experienced leader from development through commercialization. Prior to BMS, her biomarker-focused roles at Merck included companion diagnostics, project management, regulatory affairs, commercial and medical affairs. Prior, she held biotech/CRO roles ranging from business development to laboratory operations. She was the scientific lead for the first FDA-approved PD-L1 CDx for immuno-oncology, and has co-authored 95+ publications (e.g. NEJM/Lancet). Dolled-Filhart holds a BA from Cornell University and MPhil/PhD from Yale University